Technology Overview

Clinical and research laboratories are increasingly adopting multi‑marker panels to improve diagnosis, guide therapy selection, and monitor treatment response. Traditional formats such as ELISA plates and lateral flow strips rely on optical or enzymatic signals, which begin to interfere with one another as panel complexity increases, forcing compromises between panel size, sensitivity, and throughput. Mass spectrometry offers superior resolution and quantitative performance but has been difficult to integrate into routine immunoassays because existing label chemistries and workflows were not designed for MS‑based readouts.

ElectroTag addresses this gap by pairing each capture antibody with a small peptide “barcode” engineered for mass‑spectrometric detection. All reporter peptides share the same precursor mass but generate distinct fragmentation patterns, allowing many biomarkers to be cleanly resolved in a single measurement. After a standard sandwich immunoassay, the reporter peptides are released and analyzed by tandem mass spectrometry, where their fragment signatures serve as unique identifiers and quantitative signals for each target. This architecture supports high‑plex panels without optical signal overlap, while preserving a front‑end workflow that is familiar to immunoassay laboratories.

Modality

ElectroTag is an in‑vitro assay platform that combines antibody‑based capture with mass‑spectrometry readout of peptide reporters. The system employs antibody–peptide conjugates with cleavable linkers and is compatible with widely available tandem mass spectrometers, including standard benchtop and emerging compact instruments.

Target

The platform is designed to quantify disease‑associated protein biomarkers in common clinical matrices such as blood, serum, plasma, urine, and saliva. Its modular antibody‑and‑reporter design enables rapid configuration of customized multi‑analyte panels aligned with specific clinical indications or research needs.

Application

ElectroTag is intended for multiplex diagnostic testing in areas such as infectious diseases, oncology, and other conditions where multi‑marker signatures enhance clinical decision‑making. The platform can be deployed in centralized hospital and reference laboratories, specialized research facilities, and advanced decentralized settings that require scalable, high‑confidence protein measurements, with a future pathway toward near‑patient use as compact mass‑spectrometry systems mature.